(Age-specific institutional normal ranges)* | patient 1 see footnotes for age | patient 2† |
---|---|---|
Before substitution; (mg/dL) | ||
IgG | 1362 (473–1385)‡ | 386 (442–918) |
IgG1 | 952 (370–1000) ‡ | 270 (290–820) |
IgG2 | 231 (72–340)‡ | 100 (38–240) |
IgG3 | 74 (13–133)‡ | 6 (15–107) |
IgG4d | 106 (0–158)‡ | 3 (0–62) |
IgA (mg/dL) | 70 (39–147)‡ | 61 (2–98) |
IgM (mg/dL) | 131 (20–92)‡ | 0.07 (12–104) |
IgE (IU/mL) | 4.6 (0–100]‡ | 5.7 |
IgD (mg/L) | 6.43‡ | 6.4 |
Antitetanus toxoid IgG (IU/mL) | 6.94‡ | 4.42 |
Antidiphtheria toxoid IgG (IU/mL) | 0.43‡ | 1.35 |
Antipneumococci capsule polysaccharide | ||
Antibodies (after threefold 13-valent conjugated vaccine) | titers‡: IgG: 1:94; IgM:1:300 | IgG concentration: 166.88 mg/L |
Antihaemophilus influenzae b IgG (mg/L) | 9‡ | 3.23 |
Antimeningococci C antibodies (after 1-× conjugated MenC vaccine): | IgG‡: 1:105 | n.d. |
IgM‡: 1:28 | ||
Anti hepatitis B IgG | n.d. | >1000 mIU/mL |
Anti EBV-IgG | n.d. | neg. |
Anti CMV-IgG | n.d. | neg. |
Anti varicella-IgG | n.d. | 48 mIU/mL |
CH50/AH50 (U/mL) | >300‡ | n.d. |
Mannan-binding lectin (MBL) (ng/mL) | 273 (>300)‡ | 17.8 (>300) |
MBL2 genotype: analysis of five genomic polymorphisms: codon 52 (CGT>TGT); codon 54 (GGC> GAC); codon 57 (GGA>GAA); promoter −550 (G>C); promoter −221 (G>C) | LXA/LYB; (= codon 54 homozygous and promoter −550 heterozygous polymorphism) | n.d. |
*Normal ranges in square brackets; pathological results in bold letters.
†At repeated occasions between 20 months and 24 months of age.
‡Between the age of 4 years and 5 years.
§At 3 years.
¶At 6 years.
**At 7 years of age.
††According to the manufacturer's instructions; invitrogen/LifeTechnologies Vienna, Austria.
MBL, mannan-binding lectin.